^
    Back
    Association details:
    Biomarker:BCL6 translocation
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma

    Published date:
    11/01/2018
    Excerpt:
    ...152 primary DLBCL patients treated with R-CHOP or R-CHOP-like regimen....BCL6 translocation status highlighted a subgroup of patients with a favorable outcome in the non-GCB DLBCLs independent of IPI (Figure 1F).
    DOI:
    10.1182/blood-2018-99-117958